CIA
VBIV

Cape Investment Advisory’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Cape Investment Advisory’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66
Closed -$39 – 1200
2023
Q4 		$39 Buy
+66
New +$40 ﹤0.01% 1122

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cape Investment Advisory's VBIV Position: Q1 2024 in Review

Cape Investment Advisory sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2024, closing a stake of 66 shares — an estimated $39 sold.

Cape Investment Advisory first reported a position in VBIV in Q4 2023 and held it in 1 quarter. The position peaked at $39 in Q4 2023. 36 funds tracked by Wall St. Rank hold VBIV as of Q1 2024.

  • Cape Investment Advisory reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2024 after selling out during the quarter.
  • Cape Investment Advisory sold 66 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2024, an estimated $39.
  • Cape Investment Advisory first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2023 and held it in 1 quarter.
  • Cape Investment Advisory's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $39 in Q4 2023.
  • 36 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2024.

Based on Cape Investment Advisory's 13F filing for Q1 2024, filed 21 Jun 2024.